Circio Holding Asa · OSL:CRNA
Circio Holding Asa — Corporate Update (June 2023)
22 slides from Circio Holding Asa's corporate update, Jun 15, 2023
Slide 1: Company update
Company update Erik Digman Wiklund - CEO 15 June 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the results of operations and the financial condition
Slide 3: Highlights
1 Highlights 2. circRNA program 3. TG01 KRAS program 4. HR update 3
Slide 4: 2022 year-to-date highlights
2022 year-to-date highlights Strategic shift to prioritize and accelerate development of the circRNA platform New company name Circio Holding ASA, with OSE ticker: CRNA Staff reduction of 40% - scientific operations at Karolinska Institutet in Stockholm Key IP filed and proof- of- concept data gener
Slide 5: circRNA program
2 circRNA program 3. TG01 KRAS program 4. HR update 5
Slide 6: Despite tough market conditions, RNA-based financings increased sharply during 2021-23
Despite tough market conditions, RNA-based financings increased sharply during 2021-23 $1,287M Total deal value of RNA- based $1,187M private financings $91 $52 $M, by RNA Modality Subtype $220 $976M $401 $51 $211 circRNA represented $24 $291 >40% of the total deal $107 $173 value of all private RNA
Slide 7: circRNA is gaining momentum as a superior mRNA platform
circRNA is gaining momentum as a superior mRNA platform Licensing Series A Series A Series A+B $150M Upfront $490M $3,5B Total deal value $270M $300M May/Aug 2021 Aug 2022 April 2023 May 2023 Feb 2021 Jul 2022 Aug 2022 Oct 2022 $80M $42M $221M Undisclosed Series A Series A Series B M&A 7
Slide 8: circRNA provides a toolbox to create a novel class of medicines
circRNA provides a toolbox to create a novel class of medicines Enhanced protein Extended RNA expression durability CircRNA is resistant to exonuclease degradation, leading to vastly increased half-life microRNA Regulatory sponging functionality 8
Slide 9: circVec – Circio's proprietary vector system for intra-cellular protein expression
circVec – Circio’s proprietary vector system for intra-cellular protein expression circVec DNA vector DNA Inject circRNA biogenesis circRNA Intra- cellular protein expression 9
Slide 10: circVec is a modular genetic cassette for intra-cellular circRNA biogenesis and protein expression
circVec is a modular genetic cassette for intra- cellular circRNA biogenesis and protein expression Modular structure circVec - DNA Efficient circRNA biogenesis Genetic cassette In- built RNAi design Core circVec design IP filed 4Q´22 Vector agnostic – IP filed 1Q´23 + for use in adenoviral vectors
Slide 11: circVec achieves 15x prolonged circRNA half-life and increased protein expression vs. mRNA in vitro
circVec achieves 15x prolonged circRNA half-life and increased protein expression vs. mRNA in vitro Accumulation of circVec circRNA and protein payload over time, RT-PCR and Western blot circVec RNA stability RT-qPCR, nascent vs. total RNA RNA expression protein expression 135h vs. 9h circRNA mRNA 1
Slide 12: circVec starting point is based on nature's best design
circVec starting point is based on nature`s best design mRNA AAAAAAAA Screening of most effective circRNA- producing sequences invented by nature Linear splicing circRNA protein Backsplicing expression expression circRNA / GAPDH L1 L2 L3 L4 Expression of endogenous circRNA NGS analysis of 300+ RNAse
Slide 13: circVec design has been systematically optimized for circRNA biogenesis and protein expression
circVec design has been systematically optimized for circRNA biogenesis and protein expression Design optimization for circRNA biogenesis Efficient circRNA designs outperform mRNA circRNA-specific RT-PCR Western blot, protein expression 300 200 / GAPDH 100 Payload 0 Control Design optimization for p
Slide 14: circVec data summary: broad technical proof-of-concept established
circVec data summary: broad technical proof-of- concept established Design optimized for DNA and virus - based Enhanced and more Robust miRNA sponging highly efficient circRNA circRNA biogenesis durable protein activity confirmed biogenesis in cells Replicating and non- expression vs. mRNA Additiona
Slide 15: circVec can overcome limitations of synthetic RNA approaches and open new opportunities for circRNA
circVec can overcome limitations of synthetic RNA approaches and open new opportunities for circRNA Efficient and durable Enhanced potency, single Durable protein replacement, expression of therapeutic dose vaccine concept with without need for genome proteins in solid tumors simplified administrati
Slide 16: Circio has a unique edge in the emerging circRNA field
Circio has a unique edge in the emerging circRNA field World- leading experts in- house with over 10 years experience in circRNA biology Led by circRNA discoverer and pioneer Dr. Thomas B Hansen Differentiated vector delivery platform opening new therapeutic areas for circRNA Efficient circRNA bioge
Slide 17: TG01 KRAS program
3 TG01 KRAS program 4. HR update 17
Slide 18: The two TG01 investigator-initiated trials are open for enrolment in the USA and Norway
The two TG01 investigator-initiated trials are open for enrolment in the USA and Norway Sponsor Clinical Design Milestones Pancreatic cancer Post- surgery TG01 vaccination US IND approved TG01 monotherapy & PD1 combo Actively enrolling Clinical benefit by ctDNA tracking First patient dosed March 202
Slide 19: Phase 1 data presented at ASCO provides proof-of-concept for KRAS vaccination post-surgery
Phase 1 data presented at ASCO provides proof-of- concept for KRAS vaccination post-surgery Clearance of ctDNA observed in several patients Product: ELI- 002 KRAS vaccine Product: TG01 KRAS vaccine KRAS 12D + 12R mutations only Covers 7 KRAS mutations Monotherapy only, no PD1 combo Monotherapy & PD1
Slide 20: HR update
ZI HR update 20 ¢ircio
Slide 21: The senior management team has been adapted to increased preclinical circRNA platform focus
The senior management team has been adapted to increased preclinical circRNA platform focus Dr Erik D Wiklund Dr Lubor Gaal Dr Victor Levitsky Dr Thomas B Hansen Margrethe Sørgaard Ola Melin Chief Executive Chief Financial Chief Scientific VP & Head of VP & Head of VP & Head of Officer Officer Offic
Slide 22: circRNA is gaining strong momentum and Circio has a unique approach and delivery system
“ circRNA is gaining strong momentum and Circio has a unique approach and delivery system that opens up novel therapeutic areas for circRNA, led by a high-caliber team aiming to “ build the leading circRNA biotech Dr Erik D Wiklund – CEO 22